NASDAQ$CODX

Co-Diagnostics Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Reported financial results for the quarter ended March 31, 2024.

Co-Diagnostics announced its first quarter financial results, highlighting progress with new manufacturing facilities and plans for FDA submissions and test development.

  • Cash, cash equivalents, and marketable securities totaled $50.0 million as of March 31, 2024.
  • Opened new manufacturing facility in Salt Lake City.
  • Continued facility expansion in India to enable in-house manufacturing.
  • Committed to delivering a 510(k) submission to the FDA for new instrument and COVID-19 test kit.

Headline financials

Total Revenue

$468K

Previous: $602K-22.3%
EPS

-$0.31

Previous: -$0.20-55.0%
Adjusted EBITDA Loss

-$8.43M

No prior period
Remeasurement Gain/Loss

$450K

No prior period
Unrealized Gain/Loss

$79.9K

No prior period
Interest income, net

$363K

No prior period
Loss on JV investment

-$71K

No prior period
Income tax provision

$22.8K

No prior period
Realized gain on investments

$228K

No prior period
Stock-based compensation

$1.57M

No prior period
Capital Expenditures

-$402K

Previous: -$180K-123.6%
Free Cash Flow

-$9.71M

Previous: -$5.94M-63.7%
Net Income

-$9.31M

Previous: -$5.76M-61.8%
Operating Income

-$10.3M

Previous: -$9.95M-3.1%
Gross Profit

$233K

Previous: $99.7K+134.0%
R&D Expense

$5.68M

No prior period
Stock-Based Comp

$1.57M

Previous: $2.17M-27.6%

Revenue & EPS history

Co-Diagnostics · Revenue · Quarterly

$468K

Q1 2024-22.3%vs Q1 2023
Beat estimate in 3 of 15 quarters(20%)
ActualEstimate

Revenue by segment

Co-Diagnostics · $146K total across 1 segment · Q1 2026

  • Product
    $146K

Forward guidance

Co-Diagnostics is focused on expanding manufacturing capabilities, submitting to the FDA, and developing new tests.

Tailwinds

  • Expanding manufacturing facility in India.
  • Planning clinical evaluations for multiplex test later this year.
  • Committing to deliver a 510(k) submission to the FDA for new instrument and COVID-19 test kit in the near future.
  • Driving development of TB, multiplex respiratory, and HPV tests throughout the remainder of the year.
  • Believing in the disruptive and unique nature of new platform.

Headwinds

  • PCR platform is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
  • PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.
  • Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.
  • Actual results may differ materially from those contemplated or anticipated by such forward-looking statements.
  • There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-5.3%

Avg return

Earnings day

-3.9%

Avg return

5 days after

-4.4%

Avg return

30 days after

34%

12 / 35 earnings

Positive

+21.0%

Q1 2022

Best reaction

-32.3%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.6%+24.4%
Q3 2025-11.4%-8.1%-8.3%
Q2 2025+11.7%+6.4%+28.7%
Q1 2025-2.4%-2.8%-15.5%
Q4 2024-18.3%-8.7%-10.7%
Q3 2024-5.8%-3.3%-29.7%
Q2 2024+4.7%+9.3%+25.2%
Q1 2024-9.0%-8.2%+10.7%
Q4 2023-9.3%-6.8%+1.7%
Q3 2023-7.3%+9.8%-0.8%
Q2 2023-10.8%-6.9%-5.4%
Q1 2023+0.8%+4.9%-20.9%
Q4 2022-14.8%-34.4%-46.4%
Q3 2022+8.6%+9.7%-17.4%
Q2 2022-32.3%-37.9%-50.6%
Q1 2022+21.0%+33.8%+35.1%
Q4 2021-8.3%+4.0%-24.4%
Q3 2021+7.8%+13.1%-2.3%
Q2 2021+11.0%+15.6%+10.8%
Q1 2021+15.7%+20.4%+20.8%
Q4 2020-21.8%-31.1%-27.8%
Q3 2020-20.6%-26.0%-28.8%
Q2 2020-16.8%-21.2%-29.9%
Q1 2020-27.1%-19.5%-33.5%
Q4 2019-16.7%-10.4%+35.2%
Q3 2019-4.3%-3.9%+7.1%
Q2 2019-11.1%-8.1%-13.5%
Q1 2019-14.2%-20.3%-25.7%
Q4 2018+5.6%+0.0%-8.2%
Q3 2018+2.3%-9.3%-13.1%
Q2 2018-1.4%-4.5%-10.8%
Q1 2018-8.1%-7.0%+129.7%
Q4 2017-5.9%-11.3%-14.9%
Q3 2017-3.2%-6.8%-43.4%
Q2 2017+3.2%+9.4%+29.0%
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016
Q4 2015

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro